Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul B. Manning purchased 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were bought at an average cost of $6.00 per share, for a total transaction of $7,500,000.00. Following the completion of the acquisition, the director now directly owns 1,303,752 shares in the company, valued at $7,822,512. The trade was a 2,325.49 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Candel Therapeutics Trading Down 1.1 %
Shares of NASDAQ:CADL traded down $0.07 during midday trading on Wednesday, hitting $6.53. 4,732,863 shares of the stock were exchanged, compared to its average volume of 2,379,544. The business's 50-day moving average price is $5.33 and its 200 day moving average price is $6.02. Candel Therapeutics, Inc. has a 12 month low of $1.02 and a 12 month high of $14.60. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market capitalization of $212.07 million, a price-to-earnings ratio of -3.77 and a beta of -0.95.
Institutional Investors Weigh In On Candel Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd acquired a new stake in shares of Candel Therapeutics in the second quarter valued at about $31,000. FMR LLC acquired a new stake in Candel Therapeutics during the 3rd quarter valued at approximately $46,000. MetLife Investment Management LLC acquired a new stake in Candel Therapeutics during the 3rd quarter valued at approximately $87,000. Atom Investors LP bought a new position in Candel Therapeutics during the 3rd quarter worth approximately $103,000. Finally, Rhumbline Advisers acquired a new position in shares of Candel Therapeutics in the 2nd quarter worth approximately $143,000. 13.93% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and issued a $19.00 price target (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday.
Read Our Latest Research Report on CADL
Candel Therapeutics Company Profile
(
Get Free Report)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
See Also
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.